

Ann Arbor, MI 11/18/2014. Diapin Therapeutics, LLC., a company dedicated to the development of treatments for type 2 diabetes and cardiovascular disease, announced today the signing of a license agreement with the University of Michigan for the exclusive rights to PCT/US2014/010348 entitled “Mixed Disulfide Conjugates of Thienopyridine Compounds and Uses Thereof”. The patent covers conjugates of active form of clopidogrel (Plavix[®]) that stabilize the molecule. The work by inventors Haoming Zhang and Paul Hollenberg at the University of Michigan is critical to producing an anti-platelet therapy with the safety record of clopidogrel without the need for metabolic activation by P₄₅₀ enzymes. “Many diabetes patients as well as approximately 60% of the Asian population cannot adequately metabolize clopidogrel and therefore cannot benefit from the activity of this well studied molecule,” said Dr. Bruce Markham, Diapin’s President and CEO. Type 2 diabetes patients are at increased risk for cardiovascular complications and this novel product could permit these patients to be treated with the world’s number 1 selling anti-thrombotic agent. Diapin Therapeutics remains committed to finding novel approaches to treat type 2 diabetes.

About Plavix[®]

Plavix[®] is indicated for the reduction of atherothrombotic events in patients with a history of MI, stroke or established peripheral arterial disease. Plavix[®] is also indicated for patients with NSTEMI ACS, including those who are to be managed medically and those managed with PCI (with or without a stent) or CABG. Additionally Plavix[®] is indicated in STEMI patients. The efficacy and safety profile of Plavix[®] is well established in clinical trials with more than 100,000 patients across the full spectrum of ACS, recent MI, recent ischemic stroke and established P.A.D, and in more than 70 million patients worldwide.

Plavix[®] is marketed worldwide by sanofi-aventis and Bristol-Myers Squibb Company as Plavix[®] and Iscover[®].